Literature DB >> 32910226

Enlarged vestibular aqueduct and Mondini Malformation: audiological, clinical, radiologic and genetic features.

F Forli1, F Lazzerini2, G Auletta3, L Bruschini2, S Berrettini2,4.   

Abstract

PURPOSE: When referring to enlarged vestibular aqueduct (EVA) we should differentiate between nonsyndromic enlarged vestibular aqueduct (NSEVA) and Pendred Syndrome (PDS), a disease continuum associated with pathogenic sequence variants of Pendrin's Gene (SLC26A4) in about half of the cases. The study was aimed to analyse the clinical and audiological features of a monocentric cohort of Caucasian patients with NSEVA/PDS, their genetic assessment and morphological inner ear features.
METHODS: We retrospectively reviewed the audiologic, genetic and anamnestic data of 66 patients with NSEVA/PDS followed by our audiology service.
RESULTS: SLC26A4 mutations was significantly correlated with the presence of PDS rather than NSEVA (p < 0.019), with the expression of inner ear malformations (p < 0.001) and with different severity of hearing loss (p = 0.001). Furthermore, patients with PDS showed significantly worse pure tone audiometry (PTA) than patients with NSEVA (p = 0.001). Anatomically normal ears presented significantly better PTA than ears associated with Mondini Malformation or isolated EVA (p < 0.001), but no statistically significative differences have been observed in PTA between patients with Mondini Malformation and isolated EVA.
CONCLUSION: NSEVA/PDS must be investigated in all the congenital hearing loss, but also in progressive, late onset, stepwise forms. Even mixed or fluctuating hearing loss may constitute a sign of a NSEVA/PDS pathology. Our findings can confirm the important role of SLC26A4 mutations in determining the phenotype of isolated EVA/PDS, both for the type/degree of the malformation, the hearing impairment and the association with thyroid dysfunction.

Entities:  

Keywords:  Enlarged vestibular aqueduct; Hearing loss; Inner ear malformation; Mondini Malformation; Pendred Syndrome

Year:  2020        PMID: 32910226     DOI: 10.1007/s00405-020-06333-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  35 in total

1.  Delineating the hearing loss in children with enlarged vestibular aqueduct.

Authors:  Guangwei Zhou; Quinton Gopen; Margaret A Kenna
Journal:  Laryngoscope       Date:  2008-11       Impact factor: 3.325

2.  Congenital malformations of the inner ear: a classification based on embryogenesis.

Authors:  R K Jackler; W M Luxford; W F House
Journal:  Laryngoscope       Date:  1987-03       Impact factor: 3.325

3.  Large vestibular aqueduct syndrome: audiological, radiological, clinical, and genetic features.

Authors:  Stefano Berrettini; Francesca Forli; Fausto Bogazzi; Emanuele Neri; Luca Salvatori; Augusto Pietro Casani; Stefano Sellari Franceschini
Journal:  Am J Otolaryngol       Date:  2005 Nov-Dec       Impact factor: 1.808

4.  Non-syndromic hearing loss associated with enlarged vestibular aqueduct is caused by PDS mutations.

Authors:  S Usami; S Abe; M D Weston; H Shinkawa; G Van Camp; W J Kimberling
Journal:  Hum Genet       Date:  1999-02       Impact factor: 4.132

5.  Distal renal tubular acidosis associated with isolated large vestibular aqueduct and sensorineural hearing loss.

Authors:  Stefano Berrettini; Francesca Forli; Stefano Sellari Franceschini; Francesca Ravecca; Mauro Massimetti; Emanuele Neri
Journal:  Ann Otol Rhinol Laryngol       Date:  2002-05       Impact factor: 1.547

Review 6.  Cochlear implantation in children with anomalous cochleovestibular anatomy.

Authors:  Blake C Papsin
Journal:  Laryngoscope       Date:  2005-01       Impact factor: 3.325

Review 7.  Cochlear implantation in inner ear malformations--a review article.

Authors:  Levent Sennaroglu
Journal:  Cochlear Implants Int       Date:  2009-04-08

8.  Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct.

Authors:  F Bogazzi; D Russo; F Raggi; F Ultimieri; S Berrettini; F Forli; L Grasso; C Ceccarelli; S Mariotti; A Pinchera; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

9.  Genotype-phenotype correlations for SLC26A4-related deafness.

Authors:  Hela Azaiez; Tao Yang; Sai Prasad; Jessica L Sorensen; Carla J Nishimura; William J Kimberling; Richard J H Smith
Journal:  Hum Genet       Date:  2007-08-10       Impact factor: 4.132

10.  Large vestibular aqueduct in distal renal tubular acidosis. High-resolution MR in three cases.

Authors:  S Berrettini; E Neri; F Forli; M Panconi; M Massimetti; F Ravecca; S Sellari-Franceschini; C Bartolozzi
Journal:  Acta Radiol       Date:  2001-05       Impact factor: 1.701

View more
  4 in total

1.  Exploring the missing heritability in subjects with hearing loss, enlarged vestibular aqueducts, and a single or no pathogenic SLC26A4 variant.

Authors:  Jeroen J Smits; Suzanne E de Bruijn; Cornelis P Lanting; Jaap Oostrik; Luke O'Gorman; Tuomo Mantere; Frans P M Cremers; Susanne Roosing; Helger G Yntema; Erik de Vrieze; Ronny Derks; Alexander Hoischen; Sjoert A H Pegge; Kornelia Neveling; Ronald J E Pennings; Hannie Kremer
Journal:  Hum Genet       Date:  2021-08-19       Impact factor: 5.881

2.  Pendred Syndrome, or Not Pendred Syndrome? That Is the Question.

Authors:  Paola Tesolin; Sofia Fiorino; Stefania Lenarduzzi; Elisa Rubinato; Elisabetta Cattaruzzi; Lydie Ammar; Veronica Castro; Eva Orzan; Claudio Granata; Daniele Dell'Orco; Anna Morgan; Giorgia Girotto
Journal:  Genes (Basel)       Date:  2021-10-01       Impact factor: 4.096

Review 3.  Genetic architecture and phenotypic landscape of SLC26A4-related hearing loss.

Authors:  Keiji Honda; Andrew J Griffith
Journal:  Hum Genet       Date:  2021-08-03       Impact factor: 4.132

4.  Auditory and imaging markers of atypical enlarged vestibular aqueduct.

Authors:  Linsheng Wang; Yuanlin Qin; Laimin Zhu; Xiaoyu Li; Yueqin Chen; Lihong Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-09       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.